GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » Net Current Asset Value

Geovax Labs (Geovax Labs) Net Current Asset Value : $0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Geovax Labs's net current asset value per share for the quarter that ended in Dec. 2023 was $0.00.

The historical rank and industry rank for Geovax Labs's Net Current Asset Value or its related term are showing as below:

GOVXW' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.69   Med: 3.98   Max: 13551677.02
Current: 0.71

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Geovax Labs was 13551677.02. The lowest was 0.69. And the median was 3.98.

GOVXW's Price-to-Net-Current-Asset-Value is ranked better than
92.04% of 1030 companies
in the Biotechnology industry
Industry Median: 4.025 vs GOVXW: 0.71

Geovax Labs Net Current Asset Value Historical Data

The historical data trend for Geovax Labs's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Net Current Asset Value Chart

Geovax Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Geovax Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Geovax Labs's Net Current Asset Value

For the Biotechnology subindustry, Geovax Labs's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Price-to-Net-Current-Asset-Value falls into.



Geovax Labs Net Current Asset Value Calculation

Geovax Labs's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(7.886-3.52-0-0)/0
=N/A

Geovax Labs's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(7.886-3.52-0-0)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geovax Labs  (NAS:GOVXW) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Geovax Labs Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (Geovax Labs) Business Description

Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.